Strontium Ranelate
Indication
Treatment of severe osteoporosis
- in postmenopausal women;
- in adult men
at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures.
The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks
MHRA Drug Safety Update - Strontium ranelate: cardiovascular risk—restricted indication and new monitoring requirements (March 2014)
Amber level 0
Brand:
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
The EMA has considered that strontium ranelate should only be used by people for whom there are no other treatments for osteoporosis. The cardiovascular risks identified with strontium ranelate may be sufficiently reduced in this population by restricting its use to people without cardiovascular contraindications. Please see link to the Drug Safety Update on the MHRA website for further information (in supporting documents below)
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: